Akero Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	1,548	1,301	2,563	738	896	634
Market Cap Growth	-20.87%	-49.24%	247.29%	-17.63%	41.33%	-
Enterprise Value	679	777	2,222	551	629	497
PE Ratio	-	-8.57	-22.87	-7.32	-11.31	-14.49
PB Ratio	1.83	2.43	7.85	4.36	3.46	4.92
P/FCF Ratio	-9.12	-8.95	-27.70	-9.26	-12.63	-17.79
P/OCF Ratio	-9.12	-8.95	-27.70	-9.26	-12.65	-17.79
EV/EBITDA Ratio	-3.16	-5.23	-20.01	-5.48	-7.96	-11.37
EV/EBIT Ratio	-3.15	-5.22	-19.96	-5.47	-7.94	-11.37
EV/FCF Ratio	-3.55	-5.34	-24.01	-6.91	-8.86	-13.96
Debt / Equity Ratio	0.04	0.05	0.03	0.01	0.01	-
Debt / EBITDA Ratio	-0.20	-0.17	-0.10	-0.01	-0.02	-
Debt / FCF Ratio	-0.23	-0.18	-0.11	-0.02	-0.02	-
Quick Ratio	29.86	28.75	18.42	7.49	20.47	14.56
Current Ratio	30.12	29.27	18.61	7.70	20.70	14.74
Interest Coverage	-48.35	-47.97	-150.60	-	-	-
Return on Equity (ROE)	-27.80%	-29.70%	-46.40%	-48.30%	-41.30%	-46.60%
Return on Assets (ROA)	-25.70%	-27.20%	-41.10%	-44.10%	-38.90%	-33.40%
Return on Capital (ROIC)	-23.14%	-30.81%	-34.15%	-59.20%	-30.80%	-35.46%
Earnings Yield	-11.58%	-11.67%	-4.37%	-13.66%	-8.84%	-6.90%
FCF Yield	-10.07%	-11.17%	-3.61%	-10.80%	-7.92%	-5.62%
Buyback Yield / Dilution	-26.34%	-34.84%	-11.94%	-10.69%	-108.77%	-14474.75%
Total Shareholder Return	-26.34%	-34.84%	-11.94%	-10.69%	-108.77%	-14474.75%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).